Tacere Therapeutics develops drugs for human conditions using RNA interference (RNAi) and ddRNAi gene-silencing technology from Benitec Biopharma. This approach, called Expressed RNAi, promises lasting treatment or cure with a single dose.
Our most advanced drug program – TT-034 for Hepatitis C – has commenced Phase l/lla clinical trial, with the first human dosed in May 2014. Our pipeline also includes drugs to treat Age-Related Macular DegenerationTacere Therapeutics is a Benitec Biopharma company.
Our biological drugs target and silence unwanted genes, safely and with lasting effect.
TT-034, our drug to treat Hepatitis C
with a single dose, has entered human clinical trials. More
July 21, 2014
HCV Trial Update
July 11, 2014
Attachment to Guidance on Trials Announcement
May 12, 2014
Update on Hepatitis C Trial
March 13, 2014
HCV Patient Dosing Timing